An estimated 80,000 people live with epilepsy in Switzerland. Life Science Communication has been working on this on behalf of Epi-Suisse to launch the awareness and education campaign with the hashtag #Epilepsy Why in May 2022. The campaign aims to raise awareness about the needs of people with epilepsy and the challenges they face every day.
For the Italian company Arvelle – Angelini Pharma, Life Science Communication is accompanying the launch of a new treatment option for people with focal epilepsy. Until now, this has had inadequate seizure control despite treatment, which has had a negative impact on their lives as well as those of their relatives. Life Science Communication supports Arvelle – Angelini Pharma with PR work, the creation of marketing materials, the implementation of events and symposia as well as communication with physicians.
